CGRP blockers

Teva calls off CGRP drug discovery and development pact, returns preclinical asset to Sosei
Teva calls off CGRP drug discovery and development pact, returns preclinical asset to Sosei
Endpoints
Teva Pharmaceutical
CGRP blockers
R&D
drug development
Heptares Therapeutics
Flag link:
In latest blow to Teva, CGRP migraine med delayed while rivals race towards the finish line
In latest blow to Teva, CGRP migraine med delayed while rivals race towards the finish line
Endpoints
Teva Pharmaceutical
migraines
CGRP blockers
fremanezumab
Flag link:
Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data
Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data
Endpoints
Amgen
CGRP blockers
migraines
Aimovig
erenumab
Flag link:
Amgen And Novartis: First Mover Advantage Is A Must
Amgen And Novartis: First Mover Advantage Is A Must
Seeking Alpha
Amgen
Novartis
migraines
erenumab
CGRP blockers
Flag link:
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
Endpoints
Novartis
Amgen
CGRP blockers
migraines
erenumab
Flag link:
Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field
Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field
Endpoints
Novartis
Amgen
CGRP blockers
migraines
erenumab
Flag link:
The drug industry might finally have an answer for migraines
The drug industry might finally have an answer for migraines
Stat
migraines
Amgen
Eli Lilly
Alder Biopharma
Teva Pharmaceutical
CGRP blockers
Flag link: